Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Nov 01, 2024
- Pharmaceuticals
- R&D
Verastem Oncology’s Announcement Regarding Avutometinib (Completion of Rolling NDA Submission to the FDA for Avutometinib plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer)
TOKYO, November 1, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Verastem Oncology issued a press release on October 31 about completion of rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avutometinib plus defactinib as a treatment for recurrent KRAS mutant low-grade serous ovarian cancer. Avutometinib, a RAF/MEK clamp, was created by Chugai, and its clinical development is being conducted by Verastem Oncology
Please refer to the link below for details of the Verastem Oncology’s press release:
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-completes-rolling-nda-submission-fda
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
